Concurrent Investment Advisors LLC Acquires 6,576 Shares of Alnylam Pharmaceuticals, Inc. $ALNY

Key Points

• Concurrent Investment Advisors increased its Alnylam Pharmaceuticals stake by 695.9% in the second quarter, purchasing 6,576 additional shares to own 7,521 shares valued at approximately $2.26 million.
• Institutional investors hold 92.97% of Alnylam’s shares, with several major funds—including Norges Bank, Legal & General, and AQR Capital Management—recently establishing or expanding positions.
• Analysts maintain a generally positive outlook, with a consensus “Moderate Buy” rating and a $382.96 price target. Alnylam also reported quarterly EPS of $1.84, exceeding estimates, while revenue increased 66.9% year over year.

Concurrent Investment Advisors LLC raised its holdings in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 695.9% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 7,521 shares of the biopharmaceutical company's stock after purchasing an additional 6,576 shares during the quarter. Concurrent Investment Advisors LLC's holdings in Alnylam Pharmaceuticals were worth $2,264,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. Norges Bank bought a new position in shares of Alnylam Pharmaceuticals in the fourth quarter valued at about $895,816,000. Legal & General Group Plc bought a new stake in shares of Alnylam Pharmaceuticals during the 2nd quarter worth about $278,321,000. Qube Research & Technologies Ltd acquired a new position in Alnylam Pharmaceuticals in the 3rd quarter valued at about $369,943,000. AQR Capital Management LLC grew its stake in Alnylam Pharmaceuticals by 295.2% in the 3rd quarter. AQR Capital Management LLC now owns 744,008 shares of the biopharmaceutical company's stock valued at $336,009,000 after buying an additional 555,759 shares during the last quarter. Finally, Bank of New York Mellon Corp bought a new position in Alnylam Pharmaceuticals in the 2nd quarter valued at about $148,128,000. 92.97% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on ALNY shares. BMO Capital Markets restated an "outperform" rating on shares of Alnylam Pharmaceuticals in a research report on Monday, August 31st. TD Cowen reaffirmed a "buy" rating on shares of Alnylam Pharmaceuticals in a research report on Monday, August 31st. Royal Bank Of Canada dropped their price target on Alnylam Pharmaceuticals from $445.00 to $350.00 and set an "outperform" rating for the company in a report on Friday, July 31st. Weiss Ratings upgraded Alnylam Pharmaceuticals from a "hold (c-)" rating to a "hold (c)" rating in a research note on Friday, July 31st. Finally, Needham & Company LLC decreased their price objective on Alnylam Pharmaceuticals from $510.00 to $357.00 and set a "buy" rating on the stock in a report on Thursday, July 30th. Two research analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and five have assigned a Hold rating to the company. Based on data from MarketBeat, Alnylam Pharmaceuticals currently has a consensus rating of "Moderate Buy" and a consensus price target of $382.96.

Alnylam Pharmaceuticals Price Performance

Shares of ALNY stock opened at $260.10 on Wednesday. The company has a quick ratio of 2.99, a current ratio of 3.05 and a debt-to-equity ratio of 0.75. Alnylam Pharmaceuticals, Inc. has a twelve month low of $197.81 and a twelve month high of $495.55. The company has a market cap of $34.80 billion, a P/E ratio of 48.35 and a beta of 0.31. The business has a fifty day simple moving average of $257.89 and a 200 day simple moving average of $290.47.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last issued its earnings results on Thursday, July 30th. The biopharmaceutical company reported $1.84 EPS for the quarter, topping the consensus estimate of $1.63 by $0.21. The firm had revenue of $1.29 billion during the quarter, compared to the consensus estimate of $1.32 billion. Alnylam Pharmaceuticals had a return on equity of 84.93% and a net margin of 15.26%.The business's quarterly revenue was up 66.9% on a year-over-year basis. During the same quarter in the previous year, the firm earned ($0.51) earnings per share. On average, sell-side analysts forecast that Alnylam Pharmaceuticals, Inc. will post 6.71 EPS for the current fiscal year.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc NASDAQ: ALNY is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.

Want to see what other hedge funds are holding ALNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.